UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Estimating the Opportunity for Early Detection of Ovarian Cancer Using Individual-Patient Data from a Large Randomized Controlled Trial

Ryser, Marc D; Holloway, Shannon T; Morsomme, Raphaël; Ryan, Andy; Apostolidou, Sophia; Gentry-Maharaj, Aleksandra; Gogebakan, Kemal Caglar; ... Etzioni, Ruth; + view all (2025) Estimating the Opportunity for Early Detection of Ovarian Cancer Using Individual-Patient Data from a Large Randomized Controlled Trial. Cancer Epidemiology, Biomarkers & Prevention 10.1158/1055-9965.EPI-25-0498.

[thumbnail of epi-25-0498.pdf] Text
epi-25-0498.pdf - Accepted Version
Access restricted to UCL open access staff until 15 August 2026.

Download (1MB)

Abstract

BACKGROUND: The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) did not detect a reduction in ovarian cancer (OC) mortality with either multimodal screening (MMS) or transvaginal ultrasound screening (USS) compared to no screening. The trial data provide an invaluable resource to quantify the opportunity for interception in OC. METHODS: We used Bayesian inference to estimate OC natural history based on individual screening and cancer diagnosis records from UKCTOCS, a randomized controlled OC screening trial conducted in England, Wales, and Northern Ireland. The trial included 202,638 women aged 50 to 74 years with no family history of OC, randomized in a 1:1:2 ratio to annual MMS (serum CA125 interpreted using the Risk of Ovarian Cancer Algorithm), annual USS, or no screening. The current analysis included 199,499 women, with 674,806 screens and 2,025 cancer diagnoses. RESULTS: Among high-grade serous cancers (HGSCs), the estimated preclinical detectable phase (PCDP) was 1.7 years (95% credible interval [CI], 1.3-2.2), compared with 7.8 years (95% CI, 5.7-10.6) for non-HGSCs. The PCDP depended on screening modality: for HGSCs, it was longer in the MMS arm (2.2 years) compared with the USS arm (0.8 years), whereas for non-HGSCs, it was shorter in the MMS arm (2.7 years) compared with the USS arm (8.2 years). CONCLUSIONS: The interception opportunity for OC strongly depends on histological subtype and screening modality. IMPACT: Achieving a clinically significant benefit of OC early detection will require prolonging the interception window through judicious combination of first- and second-line tests.

Type: Article
Title: Estimating the Opportunity for Early Detection of Ovarian Cancer Using Individual-Patient Data from a Large Randomized Controlled Trial
Location: United States
DOI: 10.1158/1055-9965.EPI-25-0498
Publisher version: https://doi.org/10.1158/1055-9965.EPI-25-0498
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL EGA Institute for Womens Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL
URI: https://discovery.ucl.ac.uk/id/eprint/10212377
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item